Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage ...(( ADHD )); the impact of competitive pro...),Health

Date:4/3/2008

("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on Shire's ADHD franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2007.

*Dosing based on as few as three tablets per day. Number of meals per day may vary. To achieve certain doses, additional tablets may be required.

'/>"/>

SOURCE Shire Pharmaceuticals Copyright©2008 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Orqis(R) Medicals Cancion(R) System Significantly Increases Cardiac Performance
2. New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
5. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
6. Bone Mineral Content Continues to Increase in Obese Adolescents During Weight Loss
7. Study Linking Increased Risk of Death to Severe Psoriasis a Call to Action
8. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
9. FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis
10. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
11. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies